Breath Molecular Cancer Early Screening System BreathDX Deep Dive: Detecting Molecular Markers of 20 Early-Stage Cancers with a Single Breath

Breath Molecular Cancer Early Screening System BreathDX Deep Dive

In October 2030, Israeli medical technology company NanoScent published the multi-center clinical trial results of its BreathDX breath cancer early screening system in Nature Biotechnology. In a prospective study involving 18,000 subjects, BreathDX achieved 82% sensitivity and 91% specificity for early-stage (Stage I and II) detection of 20 common cancers.

BreathDX's operating principle is based on a known biological fact: cancer cells have different metabolic patterns from normal cells and produce characteristic combinations of volatile organic compounds (VOCs). These VOCs reach the lungs via the bloodstream and are exhaled. BreathDX uses a high-sensitivity mass spectrometer to detect the concentration patterns of over 300 VOCs in exhaled breath, then employs AI algorithms to identify cancer-associated molecular patterns.

NanoScent CTO Yossi Yacoby explained the technical approach: "Detecting a single VOC cannot diagnose cancer, because many benign conditions produce similar metabolites. However, the concentration pattern of multiple VOCs — the 'molecular fingerprint' — is highly cancer-specific. Our AI model, trained on over 500,000 breath samples, can identify subtle patterns that human analysts cannot detect."

BreathDX's testing process is extremely simple: the subject breathes into a disposable mouthpiece for 5 seconds, and the sample is analyzed within 3 minutes. A single test costs approximately $25, far less than the hundreds of dollars for traditional imaging screening.

In clinical trials, BreathDX showed the highest early detection sensitivity for lung cancer (89%), followed by pancreatic cancer (84%) and liver cancer (79%). Notably, BreathDX demonstrated high sensitivity for pancreatic and ovarian cancers, which are traditionally difficult to detect with conventional screening methods.

The system's limitation is its inability to pinpoint the exact tumor location — BreathDX can only indicate "possible cancer presence," with diagnosis still requiring imaging and biopsy. However, researchers believe BreathDX's value lies in serving as a large-scale initial screening tool to help high-risk populations detect cancer early.

NanoScent plans to launch BreathDX in European and Israeli markets by 2031, with US FDA approval currently in progress. The company has signed a cooperation agreement with Philips to integrate BreathDX into Philips's health management platform.